# Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma

> **NCT02099292** · PHASE2 · COMPLETED · sponsor: **Georg Hess, MD** · enrollment: 103 (actual)

## Conditions studied

- Relapsed Non-Hodgkin-Lymphoma

## Interventions

- **DRUG:** Rituximab and DexaBEAM

## Key facts

- **NCT ID:** NCT02099292
- **Lead sponsor:** Georg Hess, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2005-05
- **Final completion:** 2014-03
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2014-03-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02099292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02099292, "Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02099292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*